ncRNAs in Exosomes of Cholangiocarcinoma

Overview

Exosomes are part of extracellular vesicles(EVs), and can be secreted into the environment by many types of cells. It has been demonstrated that the content and function of exosomes depends on the originating cell and the conditions under which they are produced.Exosomes contain proteins,RNAs and lipid,which may transfer biological information and activities from donor cells to receptor cells. Non-coding RNAs are involved in many biological activities including tumor growth and metastasis. In this prospective translational study, preclinical and clinical phases have been designed. On the first step, the main goal is to characterize the ncRNAs of cholangiocarcinoma derived exosomes. This exosome biomarker may provide a useful diagnostic tool. As a second step, the study will evaluate the prognostic and predictive value of cholangiocarcinoma exosomes levels in plasma in a prospectively recruited cohort of cholangiocarcinoma patients before and after surgical resection.

Full Title of Study: “Exosomes-derived ncRNAs As Biomarkers In Cholangiocarcinoma Patients”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 31, 2020

Arms, Groups and Cohorts

  • cholangiocarcinoma patients
    • cholangiocarcinoma patients without any anti-cancer therapy
  • benign biliary stricture patients
    • benign biliary stricture patients without any therapy targeting the stricture

Clinical Trial Outcome Measures

Primary Measures

  • Characterization of the ncRNAs
    • Time Frame: Up to 3 years from start of study
    • Characterization of the ncRNAs in tumor derived exosomes from cholangiocarcinoma patients before anti-cancer therapies and benign biliary stricture patients

Secondary Measures

  • Overall survival
    • Time Frame: Up to 3 years from start of the study
    • Correlation of exosomes-derived ncRNAs(at baseline and monthly during therapy until death) and time-to-event end-points
  • Progression-free survival
    • Time Frame: Up to 3 years from start of the study
    • Correlation of exosomes-derived ncRNAs(at baseline and monthly during therapy until tumor progression) and time-to-event end-points

Participating in This Clinical Trial

Inclusion Criteria

  • 1.Provide signed informed consent. The subject is capable of understanding and complying with parameters as outlined in the protocol and able to sign informed consent, approved by the Independent Ethic Committee (IEC)/Institutional Review Board (IRB) prior to the initiation of any study-specific procedures. 2.Men or women aged >= 18 years. 3.Histology- or imaging-confirmed bile duct stricture. 4.Metastatic disease or locally advanced disease not amenable to curative surgery. 5.Radiographically assessable, non-measurable disease or measurable disease as per RECIST criteria. 6.Life expectancy of at least 8 weeks from the time of enrollment. 7.No other malignancy within the past 5 years. 8.No prior chemotherapy for advanced disease. Exclusion Criteria:

  • 1.Pregnant or lactating females. 2.Significant neurological or psychiatric disorders (psychotic disorders, dementia or seizures) that would prohibit the understanding and giving of informed consent. 3.Active Hepatitis B or C or history of an HIV infection. 4.Active uncontrolled infection.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Second Hospital of Nanjing Medical University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lin Miao, MD, Principal Investigator, Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
  • Overall Contact(s)
    • Lin Miao, MD, 086-25-58509932, miaolinxh@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.